Surveillance of Pancreatic Health After Diabetes Diagnosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-84
SponsorUniversity Hospital Southampton NHS Foundation Trust
About this trial
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months.
Participants will:
* attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.
Eligibility criteria
Qualifiers
50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
Haemoglobin A1c (HbA1c) ≥ 48 or 6.5% and/or confirmed type II DM diagnosed within the last 180 days (+20 days flexibility allowance)
Willing to provide up to 30 mL of blood for each study visit
Willing and eligible to undergo MRI scan (or CT scan if MRI is contraindicated)
Disqualifiers
Prior type I or type II DM diagnosis > 6 months
A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
Under investigation for pancreatic cancer / pancreatic cyst
Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
Trial design
Treatments tested in this trial
- Avantect Pancreatic Cancer Test
Treatment groups
15,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Hospital Southampton NHS Foundation Trust
Lead sponsor
ClearNote Health
Collaborator
Source ClinicalTrials.gov